Quick Answer
Karyopharm Therapeutics Inc. reported Operating Income Loss of -$90.71 million for the year ending 2025.
- Karyopharm Therapeutics Inc. showed an increase of +24.1% in Operating Income Loss from 2024 to 2025.
- This data is from Karyopharm Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: -$9.32 million | Q4 2013: -$12.15 million | Q1 2014: -$13.71 million | Q2 2014: -$16.45 million | Q3 2014: -$19.74 million | Q4 2014: -$25.94 million | Q1 2015: -$26.15 million | Q2 2015: -$33.01 million | Q3 2015: -$30.61 million | Q4 2015: -$29.30 million | Q1 2016: -$27.35 million | Q2 2016: -$30.48 million | Q3 2016: -$25.74 million | Q4 2016: -$27.17 million | Q1 2017: -$30.28 million | Q2 2017: -$29.75 million | Q3 2017: -$31.06 million | Q4 2017: -$39.45 million | Q1 2018: -$38.94 million | Q2 2018: -$34.33 million | Q3 2018: -$49.15 million | Q4 2018: -$57.46 million | Q1 2019: -$64.92 million | Q2 2019: -$41.69 million | Q3 2019: -$39.40 million | Q1 2020: -$47.36 million | Q2 2020: -$40.32 million | Q3 2020: -$47.11 million | Q1 2021: -$52.37 million | Q2 2021: -$49.05 million | Q3 2021: -$43.81 million | Q1 2022: -$34.59 million | Q2 2022: -$42.91 million | Q3 2022: -$30.84 million | Q1 2023: -$30.90 million | Q2 2023: -$29.57 million | Q3 2023: -$31.26 million | Q1 2024: -$33.76 million | Q2 2024: -$28.12 million | Q3 2024: -$26.28 million | Q1 2025: -$33.26 million | Q2 2025: -$24.39 million | Q3 2025: -$15.22 million.
- Over the full 15 years of available data (2011 to 2025), Karyopharm Therapeutics Inc.'s Operating Income Loss has declined by 779.7%.
- Historical annual values: Fiscal year 2025: -$90.71 million | Fiscal year 2024: -$119.44 million | Fiscal year 2023: -$129.54 million | Fiscal year 2022: -$142.20 million | Fiscal year 2021: -$98.27 million | Fiscal year 2020: -$171.85 million | Fiscal year 2019: -$189.28 million | Fiscal year 2018: -$179.88 million | Fiscal year 2017: -$130.54 million | Fiscal year 2016: -$110.73 million | Fiscal year 2015: -$119.08 million | Fiscal year 2014: -$75.85 million | Fiscal year 2013: -$33.95 million | Fiscal year 2012: -$15.89 million | Fiscal year 2011: -$10.31 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: